Additionally, calcimimetics that activate calcium-sensing receptors in parathyroid tissue have been utilized to clinically manage hyperparathyroidism, where they are proposed to ameliorate deleterious tissue remodeling in part by modulating autophagy43,44. This evidence concerns the gene CASR and hyperparathyroidism.